Extra radiation boost for advanced lung cancer after standard treatment
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that cannot be surgically removed. It is for those who have already completed two cycles of induction chemo and at least 40 Gy of radiation with chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have stage III non-small cell lung cancer that cannot be surgically removed
- You have already received two cycles of chemotherapy followed by at least 40 Gy of radiation with additional chemo
- Your tumors are small enough (less than 5 cm across) and limited to 1–3 spots for a precise radiation boost
- You are well enough to be active (ECOG score 0–2)
- You do not have a specific EGFR gene mutation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
This trial looks at adding two immunotherapy drugs to radiation and chemotherapy for people with stage 3 lung cancer that cannot be removed by surgery. It compares giving immunotherapy during radiation versus giving it after radiation, to see which way may help control the cancer better.
This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.